Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies
Aberrant skipping of coding exons in CD19 and CD22 compromises the response to
immunotherapy in B-cell malignancies. Here, we showed that the MS4A1 gene encoding …
immunotherapy in B-cell malignancies. Here, we showed that the MS4A1 gene encoding …
New CD20 alternative splice variants: molecular identification and differential expression within hematological B cell malignancies
C Gamonet, E Bole-Richard, A Delherme… - … hematology & oncology, 2015 - Springer
Background CD20 is a B cell lineage–specific marker expressed by normal and leukemic B
cells and targeted by several antibody immunotherapies. We have previously shown that the …
cells and targeted by several antibody immunotherapies. We have previously shown that the …
Modulation of CD22 protein expression in childhood leukemia by pervasive splicing aberrations: implications for CD22-directed immunotherapies
Downregulation of surface epitopes causes postimmunotherapy relapses in B-lymphoblastic
leukemia (B-ALL). Here we demonstrate that mRNA encoding CD22 undergoes aberrant …
leukemia (B-ALL). Here we demonstrate that mRNA encoding CD22 undergoes aberrant …
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on …
I Papageorgiou, MR Loken, LE Brodersen… - Leukemia & …, 2019 - Taylor & Francis
Acute myeloid leukemia (AML) remains difficult to treat disease. While initial complete
remission (CR) rates are> 80%, overall survival remains unacceptably low due to high …
remission (CR) rates are> 80%, overall survival remains unacceptably low due to high …
Dissection of CD20 regulation in lymphoma using RNAi
CD20, encoded by MS4A1, is a cell surface glycoprotein involved in calcium signaling, 1
expressed on normal and malignant B cells. Antibodies targeting CD20 (for example …
expressed on normal and malignant B cells. Antibodies targeting CD20 (for example …
Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas
SJ Schuster, LY Huw, CR Bolen, V Maximov… - Blood, 2024 - ashpublications.org
CD20 is an established therapeutic target in B-cell malignancies. The CD20× CD3 bispecific
antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs) …
antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs) …
[HTML][HTML] Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
GS Laszlo, KH Harrington, CJ Gudgeon, ME Beddoe… - Oncotarget, 2016 - ncbi.nlm.nih.gov
With the demonstration of improved survival of some acute myeloid leukemia (AML) patients
with the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO), CD33 has been …
with the CD33 antibody-drug conjugate, gemtuzumab ozogamicin (GO), CD33 has been …
Direct long-read RNA sequencing identifies a subset of questionable exitrons likely arising from reverse transcription artifacts
Resistance to CD19-directed immunotherapies in lymphoblastic leukemia has been
attributed, among other factors, to several aberrant CD19 pre-mRNA splicing events …
attributed, among other factors, to several aberrant CD19 pre-mRNA splicing events …
Fine epitope mapping of the CD19 extracellular domain promotes design
JR Klesmith, L Wu, RR Lobb, PD Rennert… - Biochemistry, 2019 - ACS Publications
The B-cell surface protein CD19 is present throughout the cell life cycle and is uniformly
expressed in leukemias, making it a target for chimeric antigen receptor engineered immune …
expressed in leukemias, making it a target for chimeric antigen receptor engineered immune …
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
SA Beers, RR French, HTC Chan… - Blood, The Journal …, 2010 - ashpublications.org
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …